Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 | 2015-09-30 | 2014-09-30 | 2013-09-30 | 2012-09-30 | 2011-09-30 | 2010-09-30 | 2009-09-30 | 2008-09-30 | 2007-09-30 | 2006-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $669M | $829M | $4M | $241M | $243M | $138M | $88M | $169M | $16M | $31M | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $4M | $1M | $1M | $1M |
| Beneficio bruto | — | $829M | ($15M) | $228M | $243M | $138M | $88M | $169M | $16M | $31M | $0M | $0M | ($4M) | ($3M) | ($2M) | $0M | ($4M) | ($5M) | ($14M) | ($11M) | ($7M) |
| % de margen bruto | — | 100.0% | -423.7% | 94.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -2076.2% | -993.2% | -1090.8% | 9.5% | -698.7% | -139.9% | -1039.8% | -874.8% | -1135.7% |
| Ingresos operativos (EBIT) | ($226M) | $98M | ($601M) | ($205M) | ($179M) | ($149M) | ($93M) | $61M | ($56M) | ($37M) | ($82M) | ($96M) | ($53M) | ($25M) | ($21M) | ($10M) | ($9M) | ($20M) | ($35M) | ($38M) | ($20M) |
| % de margen operativo | -33.8% | 11.9% | -16927.1% | -85.2% | -73.4% | -107.8% | -105.9% | 36.2% | -346.5% | -117.8% | -51627.1% | -25124.1% | -30443.6% | -8471.3% | -14358.6% | -3319.5% | -1419.5% | -520.5% | -2685.9% | -3141.4% | -3439.9% |
| Ingresos netos | ($320M) | ($2M) | ($599M) | ($205M) | ($176M) | ($141M) | ($85M) | $68M | ($54M) | ($34M) | ($82M) | ($92M) | ($59M) | ($31M) | ($21M) | ($3M) | ($6M) | ($19M) | ($27M) | ($30M) | ($19M) |
| % de margen neto | -47.8% | -0.2% | -16882.4% | -85.3% | -72.6% | -101.8% | -96.1% | 40.3% | -337.3% | -109.5% | -51614.6% | -24068.3% | -33503.0% | -10729.2% | -14383.6% | -1056.6% | -931.2% | -513.8% | -2078.7% | -2477.7% | -3190.3% |
| EBITDA | — | $165M | ($562M) | ($176M) | ($168M) | ($133M) | ($87M) | $66M | ($51M) | ($32M) | ($76M) | ($94M) | ($50M) | ($22M) | ($19M) | ($10M) | ($10M) | ($19M) | ($34M) | ($37M) | ($20M) |
| Beneficio por acción (EPS) | $-2.25 | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 | $-0.84 | $0.69 | $-0.65 | $-0.47 | $-1.34 | $-1.60 | $-1.25 | $-1.30 | $-1.90 | $-0.44 | $-0.90 | $-4.27 | $-6.91 | $-8.35 | $-5.95 |
| Acciones en circulación (M) | — | 134M | 120M | 107M | 105M | 104M | 101M | 99M | 84M | 74M | 61M | 57M | 47M | 24M | 11M | 7M | 6M | 5M | 4M | 4M | 3M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de ARWR. /companies/us/ARWR
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms